MedTrace Logo

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

NCT06137755 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-11-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.

Conditions

  • Vaccine-Preventable Diseases
  • Herpes Zoster

Interventions

BIOLOGICAL

CVI-VZV-001

Investigational Product

BIOLOGICAL

Shingrix

Investigational Product

Sponsors & Collaborators

  • CHA Vaccine Institute Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jeonghyeon Choi · The Catholic University of Korea Eunpyeong St. Mary's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2025-03-21
Completion
2025-03-21

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06137755 on ClinicalTrials.gov